

## Remicade - (100mg/vial; Injection)

|                              |                                                                                                                                                                                                                                                                      |                             |                     |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Infliximab                                                                                                                                                                                                                                                           | <b>Innovator</b>            | Janssen Pharma      |
| <b>Dosage</b>                | 100mg/vial; Injection                                                                                                                                                                                                                                                | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | None                                                                                                                                                                                                                                                                 | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                                                                                                          | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | Less Than 5                                                                                                                                                                                                                                                          | <b>Generic Launches</b>     | Less Than 5         |
| <b>Indication</b>            | To reduce signs/symptoms, inhibit progression of structural damage, and improve physical function in psoriatic arthritis and with methotrexate in moderately to severely active rheumatoid arthritis (RA). To reduce signs/symptoms of active ankylosing spondylitis |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.